Registration of securities issued in business combination transactions

Statements of Operations (Mymd Pharmaceuticals Inc.)

v3.20.4
Statements of Operations (Mymd Pharmaceuticals Inc.) - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Revenues
Operating Costs:    
General and administrative expenses (including $855,000, $3,577,550 of share-based compensation for 2020 and 2019, respectively) 4,299,062 3,372,103
Research and development expenses 7,963,678
Net Loss (17,580,609) (3,888,249)
Mymd Pharmaceuticals Inc. [Member]    
Revenues
Operating Costs:    
General and administrative expenses (including $855,000, $3,577,550 of share-based compensation for 2020 and 2019, respectively) 3,304,673 5,764,986
Research and development expenses 2,241,431 3,627,739
Option modification expense 2,009,145
Total Operating Costs 7,555,249 9,392,725
Interest Expense (1,375,216) (246,191)
Net Loss $ (8,930,465) $ (9,638,916)